Navigation Links
Pfenex Reports Second Quarter 2014 Results and Provides Business Update
Date:8/29/2014

SAN DIEGO, Aug. 29, 2014 /PRNewswire/ -- Pfenex Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company engaged in the development of high-value and difficult to manufacture proteins including biosimilar therapeutics, today provided a business update and reported financial results for the second quarter ended June 30, 2014.

"With the successful completion of our initial public offering, we have the capital to continue to advance our biosimilar product candidates, derived from our proprietary protein expression platform," stated Bertrand C. Liang, chief executive officer of Pfenex. "We expect to complete the phase 1b/2a trial for our lead product candidate, PF582, a biosimilar to Lucentis, by the end of 2014 and initiate the phase 3 trial in mid-2015." 

Business Updates

  • On July 29, 2014 we closed our initial public offering.  Including the underwriters exercise of their option to purchase additional shares, 9,429,084 shares of common stock were sold in the offering for a total capital raise of approximately $52.6 million after underwriter fees and discounts but before deducting offering expenses.
  • With the close of our initial public offering, Pfenex expanded the leadership team through the addition of two new board members, William R. Rohn and Philip R. Schneider. Mr. Rohn joined the board as chairman and brings extensive biotech industry experience having served in managerial roles at Biogen IDEC, IDEC Pharmaceuticals and Adria Laboratories. Mr. Schneider also joined the board with broad industry experience through previous management positions with IDEC Pharmaceuticals and Syntex Pharmaceuticals.
  • Financial Highlights for the three months ended June 30, 2014

  • Total revenue for the second quarter of 2014 was $3.3 million compared to $2.3 million in the second quarter of 2013.
    The increase in revenue was due to an increase in activity related to our Px563L product candidate development under
    '/>"/>

  • SOURCE Pfenex Inc.
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Pfenex Inc. Awards Glide Pharma Development Contract for a Solid Formulation of Recombinant Anthrax Vaccine
    2. Pfenex Inc. Awards Paragon Bioservices a Contract for cGMP Manufacturing of its Recombinant Protective Antigen (rPA), for Phase 1 Clinical Trial of its Anthrax Vaccine
    3. Pfenex Awarded Contract For Development Of Next Generation rPA-Based Anthrax Vaccine
    4. Discovery Labs Reports Third Quarter Financial Results and Progress on Lead Programs
    5. Verenium Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2011
    6. Interleukin Genetics Reports Third Quarter 2011 Financial Results
    7. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
    8. Nile Therapeutics Reports 2011 Third Quarter Financial Results
    9. Pharmasset Reports Fiscal Year End 2011 Financial Results
    10. Palatin Technologies, Inc. Reports First Quarter Fiscal Year 2012 Results; Teleconference and Webcast to be held on November 15, 2011
    11. SeraCare Reports Fiscal Year 2011 and Fourth Quarter Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/30/2014)... , Sept. 30, 2014 FemCap Inc., ... health announces its receipt of a patent No: US, ... cup has also received FDA clearance in the U.S., ... the CE in Europe. This patent is related to its ... this issuance, the company is releasing FemmyCycle Teen, a ...
    (Date:9/30/2014)... SoundConnect, an award ... dedicated to supporting business communication solutions, including business ... a carrier services specialist has joined ... connected and productive at all times. This growth ... businesses to cloud communications services. On a ...
    (Date:9/30/2014)... 2014 Back in the 1970’s, many companies ... per employee, which included space for circulation and file storage. ... Howell, partner at Nidea Corporate Real Estate / ITRA ... the year 2000, however, 250 square feet per employee ... come down to 175 to 225 square feet, and over ...
    (Date:9/29/2014)... Sept. 29, 2014  Ten of the most ... cartilage repair, regeneration, allograft reconstruction and research and ... world gathered to discuss the future of cartilage ... Regenerative Medicine symposium, Cartilage Regeneration: State of ... Orthopedic Biosurgery, Minced Juvenile Allograft, and State of ...
    Breaking Biology Technology:The FemmyCycle 2SoundConnect Expands Carrier Services Division 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 2ITRA Global Reports on How Companies Are Squeezing More Employees into Less Office Space 3World Renowned Experts Discuss Future Of Cartilage Regeneration 2World Renowned Experts Discuss Future Of Cartilage Regeneration 3
    ... Ill., June 30 Hospira, Inc. (NYSE: ... company, today announced agreements with MedAssets on intravenous (I.V.) ... its agreement for infusion devices. The five-year MedAssets agreements ... solutions and equipment, and July 1, 2009, for infusion ...
    ... needs, clinical uses and funding sources , , ROCKVILLE, ... in Rockville, Md., announced today that former Secretary of the ... board of directors. , , "I am excited ... battlefield and in emergency rooms throughout the US. I am ...
    ... Limited, the decentralised and point-of-care molecular diagnostics company, announced today ... Veterinary Laboratories Agency to evaluate the performance of the Enigma ... be one of the main threats to cattle (1), affecting ... closely related to classical swine fever virus, a serious disease ...
    Cached Biology Technology:Hospira Announces New Contract With MedAssets for Intravenous Solutions, Renewal of Infusion Devices Agreement 2Former Secretary of Veterans Affairs James Peake to Join the Cellphire Board of Directors 2Enigma Diagnostics Announces Successful Evaluation of the Enigma FL by the UK's Veterinary Laboratories Agency 2Enigma Diagnostics Announces Successful Evaluation of the Enigma FL by the UK's Veterinary Laboratories Agency 3
    (Date:9/30/2014)... drinking water may increase the risk of stillbirth ... led by a Boston University School of Public ... journal Environmental Health , compared 1,091 PCE-exposed ... in Cape Cod, Ma., where water was contaminated ... by the installation of vinyl-lined asbestos cement pipes. ...
    (Date:9/30/2014)... involving mice and published in the October 2014 issue ... , suggests that just because you can do it, ... of Italian scientists have found that using marijuana in ... system. This damage may result in autoimmune diseases and ... disease and rheumatoid arthritis in adulthood. , "I hope ...
    (Date:9/30/2014)... , Sept. 30, 2014  Spectra ... solutions for the biotech and power generation ... new RECONN Bioprocess Manager, an easy-to-use and ... geared towards bioprocess development laboratories. ... disparate bioreactor and analyzer systems. Accessing and ...
    Breaking Biology News(10 mins):Contaminated water linked to pregnancy complications, BU study finds 2Adolescent exposure to thc may cause immune systems to go up in smoke 2Spectra Automation Introduces RECONN Bioprocess Manager 2
    ... blood cell production and function will today be awarded ... Council,s (NHMRC) program grants scheme. The nine ... securing $107 million in program grant funding will be ... the Federal Minister for Mental Health and Ageing, the ...
    ... Parachin and the secret of her technique is enzymes that ... made from xylose then ethanol production could increase by over ... friendly fuel. Ethanol is manufactured by fermenting sugars from ... the second most common type of sugar found in nature. ...
    ... -- Software agents on assignment . . . ... organization,s network could be more secure with a system ... Oak Ridge National Laboratory,s Computational Sciences and Engineering Division. ... are being copied, excerpted, changed and stored in various ...
    Cached Biology News:$38.4M NHMRC program grants extend cancer and blood cell research 2Enzymes from garden compost could favour bioethanol production 2Story tips from the US Department of Energy's Oak Ridge National Laboratory March 2011 2
    ... Motic's B3 series of microscopes offer ... microscope required for laboratory work. Equipped with ... Super Contrast (ASC) objectives. The B3 is ... The Siedentopf binocular tube eliminates the need ...
    ... SYBR Green II RNA gel ... gel stain that has bright fluorescence when ... gels, making it ideal for use with ... scanners or standard UV transilluminators. A 500 ...
    ... SYBR Green II RNA gel stain ... has bright fluorescence when bound to RNA and ... use with either formaldehyde/agarose or polyacrylamide gels using ... stains 100 minigels. A 500 µL unit size ...
    ... Glutathion-S-transferases (GST) are a group ... the detoxification processes. The GSTs are ... Pi, Teta and microsomal. The classes ... and s Sample Size: ...
    Biology Products: